A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Name: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
License: Public Domain

Fred Hutchinson Cancer Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

recurrent b-cell non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 300255
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.